Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onatasertib + toripalimab
- Development stage
- Unknown
- Lead developer
- Antengene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Onatasertib + toripalimab is a combination therapy consisting of onatasertib (ATG-008), a second-generation small molecule inhibitor of both mTORC1 and mTORC2, and toripalimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. This combination is being evaluated for the treatment of various advanced solid tumors, including hepatocellular carcinoma and non-small cell lung cancer. The rationale for the combination is to leverage the synergistic effects of inhibiting the mTOR pathway, which is often dysregulated in cancer, while simultaneously blocking the PD-1/PD-L1 immune checkpoint to enhance the anti-tumor immune response. The TORCH-2 study, led by Sichuan University, specifically investigates this combination in patients with advanced solid tumors.
- Brand names
- Tuoyi
- Other names
- onatasertibtoripalimab
02
Targets
mTOR (Mammalian target of rapamycin kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on onatasertib + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onatasertib + toripalimab.